<div id="readability-page-1"><p>In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Viking Therapeutics, with a price target of <span id="expert-recommendation-target">$95.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Samimy covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, Ligand Pharma, and Viking Therapeutics. According to TipRanks, Samimy has an average return of <span>16.0%</span> and a 50.00% success rate on recommended stocks. </p> <p>Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $93.27.</p></div>

VKTX

LABU

<p>Stifel Nicolaus analyst Annabel Samimy has maintained a Buy rating on Viking Therapeutics (VKTX) with a price target of $95.00. The analyst consensus for VKTX is a Strong Buy, with an average price target of $93.27. Samimy has an average return of 16.0% and a 50.00% success rate on her stock recommendations, focusing on the Healthcare sector.</p>

Tip Ranks

Viking Therap

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

iShares US Pharma

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VG Health

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

ALPS Medical Breakthrough

Stifel Financial

Trevi Therapeutics

Ligand Pharmac-B

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Stifel Nicolaus Remains a Buy on Viking Therapeutics (VKTX)